{"title":"应该为愿景而不是虚假的承诺提供资金","authors":"K. Petrak","doi":"10.4172/2329-6631.1000154","DOIUrl":null,"url":null,"abstract":"Efforts to develop cell-specific drug-delivery systems have been under way for decades but have not as yet generated effective and reliable therapeutic products. The effect of repeatedly unfulfilled promises is starting to cause a decrease in funding support for research and development in this area. In this commentary, principle flaws in the current approaches are listed and discussed. Further, the manner in which approaches and paradigms for further development should change is suggested.","PeriodicalId":15589,"journal":{"name":"Journal of Developing Drugs","volume":"14 1","pages":"1-2"},"PeriodicalIF":0.0000,"publicationDate":"2016-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Visions but Not False Promises Should Be Funded\",\"authors\":\"K. Petrak\",\"doi\":\"10.4172/2329-6631.1000154\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Efforts to develop cell-specific drug-delivery systems have been under way for decades but have not as yet generated effective and reliable therapeutic products. The effect of repeatedly unfulfilled promises is starting to cause a decrease in funding support for research and development in this area. In this commentary, principle flaws in the current approaches are listed and discussed. Further, the manner in which approaches and paradigms for further development should change is suggested.\",\"PeriodicalId\":15589,\"journal\":{\"name\":\"Journal of Developing Drugs\",\"volume\":\"14 1\",\"pages\":\"1-2\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-06-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Developing Drugs\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4172/2329-6631.1000154\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Developing Drugs","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2329-6631.1000154","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Efforts to develop cell-specific drug-delivery systems have been under way for decades but have not as yet generated effective and reliable therapeutic products. The effect of repeatedly unfulfilled promises is starting to cause a decrease in funding support for research and development in this area. In this commentary, principle flaws in the current approaches are listed and discussed. Further, the manner in which approaches and paradigms for further development should change is suggested.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
